Future research needs to focus on developing more specific ERK1/2 inhibitors to reduce off-target effects, or exploring whether ERK1/2 inhibitors can be used in combination with existing diabetes drugs, which may provide new ideas for early diagnosis and precise treatment of diabetes. Here, MAPK3 is linked to diabetes mellitus.